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ABSTRACT
Background. This study was conducted to validate a
pretreatment (i.e. prior to neoadjuvant chemoradiotherapy)
pathological staging system in the resection specimen after
neoadjuvant chemoradiotherapy for esophageal cancer.
The study investigated the prognostic value of pretreatment
pathological T and N categories (prepT and prepN cate-
gories) in both an independent and a combined patient
cohort.
Methods. Patients with esophageal cancer treated with
neoadjuvant chemotherapy and esophagectomy between
2012 and 2015 were included. PrepT and prepN categories
were estimated based on the extent of tumor regression and
regressional changes of lymph nodes in the resection
specimen. The difference in Akaike’s information criterion
(DAIC) was used to assess prognostic performance. PrepN
and ypN categories were combined to determine the effect
of nodal sterilization on prognosis. A multivariable Cox
regression model was used to identify combined prepN and
ypN categories as independent prognostic factors.
Results. The prognostic strength of the prepT category
was better than the cT and ypT categories (DAIC 7.7 vs.
3.0 and 2.9, respectively), and the prognostic strength of
the prepN category was better than the cN category and
similar to the ypN category (DAIC 29.2 vs. - 1.0 and 27.9,
respectively). PrepN ? patients who became ypN0 had
significantly worse survival than prepN0 patients (2-year
overall survival 69% vs. 86% in 137 patients; p = 0.044).
Similar results were found in a combined cohort of 317
patients (2-year overall survival 62% vs. 85%; p = 0.002).
Combined prepN/ypN stage was independently associated
with overall survival.
Conclusions. These results independently confirm the
prognostic value of prepTNM staging. PrepTNM staging is
of additional prognostic value to cTNM and ypTNM.
PrepN0/ypN0 patients have a better survival than prepN ?/
ypN0 patients.
Potentially curative treatment for esophageal cancer
consists of neoadjuvant chemo(radio)therapy followed by
surgery. After neoadjuvant therapy, the percentage of
residual tumor cells and lymph node regression is of
prognostic value. Several studies investigated the impact of
tumor regression and classified histopathological response
to neoadjuvant therapy and its correlation to prognosis.1–4
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Prior to treatment, clinical staging is known to be relatively
unreliable,1,5 particularly for the N category, and an
improvement of the pretreatment stage is needed.6
Recently, Shapiro et al.7 introduced a new staging sys-
tem based on the pretreatment (i.e. prior to neoadjuvant
chemoradiotherapy) pathological tumor extent, which is
determined by the extent of regressional changes and the
presence of residual tumor cells in the resection specimen.
These regressional changes were hypothesized to reflect
the pretreatment tumor extent. The authors proved this so-
called ‘pretreatment pathological T and N staging’ (prepT
and prepN categories) to be estimated reproducibly, with
high concordance between three upper gastrointestinal
pathologists from different institutes (intraclass correlation
coefficient of between 0.7 and 0.9). It was demonstrated
that the prognostic strength of the prepT category is com-
parable with the pretreatment clinical T category (cT
category, according to the Union for International Cancer
Control [UICC] TNM Cancer Staging, 7th edition7), while
the prognostic strength of the prepN category is even better
than the pretreatment clinical N category (cN category),
and better predicts overall survival than the post-treatment
pathological N category (ypN category) alone.
The primary aim of the present study was to externally
validate the pretreatment pathological staging system of T
and N stage based on the extent of regressional changes
and the presence of residual tumor cells in the resection
specimen. In addition, we aimed to study the prognostic
value of this new staging system in the post-treatment
setting by combining the pretreatment prepN category and
the post-treatment ypN category, to distinguish between
patients who were lymph node-negative before neoadju-
vant chemoradiotherapy and patients who became lymph
node negative thanks to neoadjuvant chemoradiotherapy.
METHODS
Patient Selection
Between November 2012 and April 2015, patients
treated with curative intent for esophageal or junctional
cancer, who underwent neoadjuvant chemoradiotherapy
according to the CROSS regimen, and who had an en bloc
transthoracic esophagectomy with intrathoracic recon-
struction (Ivor–Lewis procedure) at the Department of
General, Visceral and Cancer Surgery, University of
Cologne (Chairman at that time: Professor Dr. A.H. Ho¨l-
scher) were included in this study. Patients with non-
epithelial tumors and other types of esophageal resection
and reconstruction were excluded. According to the
recently presented study protocol,1 patients who did not
receive at least 80% of the planned dose of neoadjuvant
chemoradiotherapy and who received a different neoadju-
vant chemoradiotherapy regimen, or patients with an
intraoperatively unresectable tumor, were excluded.
Patients who had\ 80% of the planned dose of neoadju-
vant chemoradiotherapy were also excluded because these
patients have limited response due to dose reduction, and
not due to tumor biology. However, the group of patients
who had \ 80% of neoadjuvant chemoradiotherapy was
\ 2% of all patients and therefore likely does not influence
the results. Patients did not participate in the CROSS trial.
The protocol of the present study was approved by the
Ethics Committee of the University Hospital of Cologne
(reference number 16-266).
Clinical Staging and Surgery
Clinical staging consisted of a standardized preoperative
work-up, including endoscopy with histological biopsy,
endoscopic ultrasonography (EUS), and thoracic and
abdominal computed tomography (CT). Clinical T and N
categories were determined by EUS and CT scanning
according to the UICC TNM Cancer Staging, 7th edition.7
Patients were classified as cN ? or cN -. For EUS, the
criteria for lymph node involvement were a short axis
diameter of C 6 mm, a specified hypoechoic pattern or
spherical contour and distinct border. On CT, lymph nodes
were considered involved if the short axis measurement
was C 1 cm, located in the expected distribution, demon-
strated altered density or enhancement, and a loss of the
fatty hilum could be observed. All patients received
neoadjuvant chemoradiotherapy 41.4 Gy and carbo-
platin/paclitaxel according to the CROSS regimen.8,9 The
standard surgical procedure of esophagectomy comprised
laparoscopic or open abdominal lymphadenectomy and
gastric tube formation, right-sided anterolateral thoraco-
tomy with an en bloc esophageal resection, and two-field
lymph node dissection. Reconstruction was performed with
a high intrathoracic stapled esophagogastrostomy. The
complete surgical approach has been described in detail
elsewhere.10,11
Post-treatment Pathological Staging
The resection specimens (primary tumor and all resected
lymph nodes) were removed en bloc and analyzed in
accordance with a standardized protocol.12 Histopatholog-
ical tumor characteristics were scored using the UICC
TNM Cancer Staging, 7th edition.7 The adapted Mandard
scoring system was used to determine the tumor regression
grade (TRG).13
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Pretreatment Pathological Staging
All resection specimen slides of all patients were
examined by two pathologists from the Department of
General Pathology and Pathological Anatomy at the
University of Cologne. In case of disagreement between
the two pathologists, consensus was achieved by consensus
discussion. After having proven interobserver agreement of
pathological estimations of pretreatment primary tumor
extent and lymph node involvement with high repro-
ducibility of prepT and prepN staging in the resection
specimen at the Department of Pathology Rotterdam, a
meeting of pathologists from both centers was organized to
improve validation of the pretreatment pathological staging
system. In accordance with Shapiro et al.,5 the original
tumor region, before neoadjuvant chemoradiotherapy, was
estimated based on the extent of regressional changes (e.g.
fibrosis, mucinous lakes, keratin pearls, and/or foreign
body giant cell reactions) and the presence of residual
tumor in the resection specimen.8,12,14 The ‘pretreatment
pathological T category’ (prepT category), reflecting the
estimated original invasion depth of the primary tumor,
was based on the extent of regressional changes in the
esophageal wall and peri-esophageal stroma. In addition,
interpretation of the ‘pretreatment pathological N category’
(prepN category), reflecting the estimated number of
originally involved lymph nodes, was dependent on the
presence of regressional changes in lymph nodes. Lymph
nodes that showed complete regression (based on patho-
logical examination) without the presence of residual
tumor were considered to have been sterilized by neoad-
juvant chemoradiotherapy. PrepT and prepN staging were
scored using the UICC TNM Cancer Staging, 7th edition.7
Data Collection and Follow-Up
Data were collected from a prospectively maintained
database. All patients were regularly evaluated during
follow-up, with 3-month intervals within the first year,
6-month intervals within the second year, and an annual
aftercare from the third year onwards. Survival was
determined by using hospital records. Overall survival was
calculated from the day of surgery until the date of death
from any cause.
Statistical Analysis
Data were described using medians and interquartile
ranges (IQRs) in the case of continuous variables, or fre-
quencies with percentages in the case of categorical
variables.
Prognosis and prognostic strength were based on overall
survival data. The difference between Akaike’s
information criterion of the model and the null model
(DAkaike’s information criterion) was calculated to mea-
sure the prognostic strength of a model.15 A higher
DAkaike’s information criterion value indicates better
prognostic ability, adjusted for the statistical complexity of
the model fit. It is calculated by the likelihood ratio (LR)
Chi square statistic of the corresponding Cox proportional
hazards model minus two times the degrees of freedom.
PrepN and ypN categories were analyzed as ordinal vari-
ables and continuous variables. For models with
continuous variables, restricted cubic splines with three
knots (corresponding with two degrees of freedom) were
used. Kaplan–Meier plots were used to depict survival, and
the log-rank test was applied to assess survival differences.
By combining the prepN and ypN categories, patients
were divided into three groups: (1) patients without nodal
involvement before and after neoadjuvant chemoradio-
therapy (prepN0/ypN0); (2) patients with nodal
involvement before neoadjuvant chemoradiotherapy and no
detectable lymph node involvement after neoadjuvant
chemoradiotherapy (prepN ?/ypN0); and (3) patients with
nodal involvement before neoadjuvant chemoradiotherapy
remaining node-positive even after neoadjuvant chemora-
diotherapy (prepN ?/ypN ?). To determine the
independent association between the combined prepN and
ypN categories and overall survival, a multivariable Cox
regression model was used. Clinicopathological charac-
teristics, which are known as prognostic factors (i.e. age,
sex, histology, TRG, and ypT stage), were included in the
multivariable model. All reported p values are two-sided
and p values \ 0.05 were considered statistically signifi-
cant. Statistical analysis was performed using SPSS 21 for
Windows (IBM Corporation, Armonk, NY, USA).
RESULTS
Clinical and Histopathological Characteristics
Overall, 137 patients were included in this study. Clin-
icopathological characteristics of patients are displayed in
Table 1. Median age at the time of surgery was 62 years;
110 patients were male (80%), 97 patients had an eso-
phageal or junctional adenocarcinoma (71%), and 40
patients had an esophageal squamous cell carcinoma
(29%). The majority of patients was clinically staged as
cT3 (90%) and cN ? (88%). In addition, 97 patients were
staged prepT3 (71%) and 82 patients were staged
prepN ? (60%). The median number of resected lymph
nodes was 28, with an IQR of 22–35.
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Comparison of PrepT Category with cT and ypT
Categories
Non-concordant prepT categories (compared with the
cT category) were found in 41 of 137 patients (30%). With
regard to the cT category, 37 patients were found to be
overstaged. Four patients had a less advanced prepT cate-
gory compared with the cT category (Table 2a). The
prognostic strength of the prepT category was higher
compared with the cT and ypT categories (DAkaike’s
information criterion 7.7 vs. 3.0 and 2.9, respectively)
[Table 3]. Overall survival curves according to the cT,
prepT, and ypT categories are shown in Fig. 1.
Comparison of PrepN Category with cN and ypN
Categories
Non-concordant prepN categories (compared with the
cN category) were found in 54 of 137 patients (39%).
Overall, 8 patients were clinically staged cN0, but showed
pathological signs of pretreatment nodal involvement in the
resection specimen. In contrast to this, 46 patients were
clinically staged cN ?, but pathological signs of pretreat-
ment nodal involvement could not be observed (Table 2b).
The prognostic strength of the prepN category was better
than the cN category, and similar to the ypN category
(DAkaike’s information criterion 29.2 vs. - 1.0 and 27.9,
respectively) [Table 3]. The overall survival curves
according to the cN, prepN, and ypN categories are shown
in Fig. 2.
Combining PrepN and ypN Categories
Two-year overall survival in patients without nodal
involvement before and after neoadjuvant chemoradio-
therapy (group 1) was 86%, compared with 69% in patients
with nodal involvement before neoadjuvant chemoradio-
therapy who became node-negative after neoadjuvant
chemoradiotherapy (group II) (p = 0.004) [Fig. 3]. Patients
who remained node-positive even after neoadjuvant
chemoradiotherapy (group III) had the worst survival (2-
year OS = 44%) compared with group I (p\ 0.001). Dif-
ferences between groups were statistically significant
(p\ 0.001). Patients who had a nodal involvement pre-
treatment, but became node-negative after neoadjuvant
chemoradiotherapy, had a statistically significantly better
2-year overall survival compared with patients who
remained node-positive after neoadjuvant chemoradio-
therapy (69% vs. 44%; p = 0.003).
TABLE 1 Clinical and histopathological characteristics of 137 patients
with esophageal or junctional cancer treated with neoadjuvant
chemoradiotherapy according to the CROSS trial, plus extended surgical
resection
n %a
Age, years
Median (p25–p75) 62 (57–68)
Sex
Female 27 20
Male 110 80
Tumor type
Squamous cell
carcinoma
40 29
Adenocarcinoma 97 71
cT category
cT1 2 1
cT2 10 7
cT3 123 90
cT4 2 1
cN category
cN0 17 12
cN-positive 120 88
prepT category
prepT1 14 10
prepT2 26 19
prepT3 97 71
prepN category
prepN0 55 40
prepN1 34 25
prepN2 35 26
prepN3 13 9
Number of nodes resected
Median (p25–p75) 28 (22–35)
ypT category
ypT0 40 29
ypT1 24 18
ypT2 22 16
ypT3 51 37
ypN category
ypN0 81 59
ypN1 21 15
ypN2 27 20
ypN3 8 6
Tumor regression grade
TRG1 40 29
TRG2 40 29
TRG3 32 23
TRG4 24 18
TRG5 –
Missing 1
TRG tumor regression grade
aData are expressed as median (interquartile range) or number (%). Per-
centages may not add up to 100 because of rounding. The Mandard
scoring system was used to determine the TRG15
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Multivariable Analysis in a Combined Patient Cohort
Finally, data of all patients from the present study
(n =137), and from the previously reported Rotterdam
Study (n =180),7 were combined and served as the basis of
a multivariable model to prove combined prepN and ypN
categories as an independent factor of prognosis. The
overall survival curves are shown in Fig. 4. Entering the
combined prepN and ypN categories in the multivariable
model could identify this additional staging parameter as
an independent prognostic factor for overall survival
(prepN ?/ypN ?; hazard ratio [HR] 2.84, 95% confidence
interval [CI] 1.82–4.44; p \ 0.01) [Table 4].
Analyses of the prognostic value of overall prepTNM
and ypTNM stage grouping showed comparable prognostic
strength of prepTNM (classified according to the cTNM
classification system) and ypTNM stage grouping (DAIC
41.2 and 40.0, respectively; supplemental analyses).
TABLE 2 Comparison of clinical (a) T and (b) N categories (cT and cN categories) with pretreatment pathological T and N categories (prepT
and prepN categories) in 137 patients
PrepT category Total
1 2 3
(a)
cT category 1 2 0 0 2
2 3 3 4 10
3 9 23 91 123
4 0 0 2 2
Total 14 26 97 137
PrepN category Total
0 1 2 3
(b)
cN category Negative 9 5 3 0 17
Positive 46 29 32 13 120
Total 55 34 35 13 137
TABLE 3 Prognostic stratification based on pretreatment clinical T category, pretreatment pathological T category, and post-treatment
pathological T category, and pretreatment clinical N category, pre treatment pathological N category, and post-treatment pathological N category
Data type LR Chi square df DAICa c-statistic (SE)
T staging
cT category Ordinal 7.0 2 3.0 0.55 (0.02)
prepT category Ordinal 11.7 2 7.7 0.60 (0.03)
ypT category Ordinal 8.9 3 2.9 0.61 (0.04)
N staging
cN category Ordinal 1.0 1 - 1.0 0.52 (0.02)
prepN category Ordinal 35.2 3 29.2 0.71 (0.04)
ypN category Ordinal 33.5 3 27.5 0.69 (0.04)
prepN category Continuous 33.9 2 29.9 0.71 (0.04)
ypN category Continuous 31.1 2 27.1 0.68 (0.04)
prepN ? ypN categories Continuous 35.4 4 27.4 0.71 (0.04)
aThis measure represents the prognostic strength of a model and is calculated by the LR Chi square statistic of the corresponding Cox
proportional hazards model minus two times the df. A higher DAIC value indicates better prognostic ability, adjusted for the statistical
complexity of the model fit17
DAIC difference between Akaike information criterion of the model and the null model, LR likelihood ratio, df degrees of freedom, c-statistic
concordance statistic, SE standard error
External Validation of PrepTNM Staging After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
DISCUSSION
The present study was conducted to validate the recently
presented pretreatment pathological staging system, based
on the extent of regressional changes and on the presence
of residual tumor cells in the resection specimen.5 In an
independent cohort of patients treated for esophageal can-
cer with neoadjuvant chemoradiotherapy followed by
surgery at another high-volume center, it was shown that
the pathological estimations of the prepT and prepN cate-
gories in the resection specimen have a high prognostic
power and can therefore be implemented in the patholog-
ical assessment.
The present study further aimed to prove the prognostic
value of the pretreatment pathological staging system in the
post-treatment setting. We confirmed that the prepT and
prepN categories have a better prognostic strength than the
clinical T and N categories. This proves the association of
this new staging parameter with postoperative overall
survival.
Shapiro et al. found that the prognostic strength of the
prepT category is similar to the clinical T category, but
worse compared with the ypT category (DAkaike’s infor-
mation criterion 1.3 vs. 2.0 and 8.9, respectively), and the
prognostic strength of the prepN category is better than the
cN category, but similar to the ypN category (DAkaike’s
information criterion 17.9 vs. 6.2 and 17.2, respectively).
In the present study, the prognostic strength of the prepT
category was even better than the ypT category. Further-
more, we found the prepN category to have a better
prognostic strength than the cN category.
However, comparing the results of both studies, it has to
be mentioned that in the present study, clinical staging of
lymph node involvement only differentiated patients in
cN ? and cN0. Of 17 clinically node-negative patients, 8
patients (47%) showed pathological signs of pretreatment
nodal involvement, explaining the low DAkaike’s infor-
mation criterion of the cN category (- 1.0) compared with
the prepN and ypN categories. In the study by Shapiro
et al.,7 37% of patients were clinically staged falsely neg-
ative with regard to lymph node involvement. The results
of both studies demonstrate the poor N-staging accuracy of
CT, EUS, and positron emission tomography (PET)/CT
scanning, emphasizing that the clinical estimation of nodal
involvement in the preoperative setting is unreliable. This
is in line with previous studies reporting similar poor
radiological cN staging accuracy,6,16–18 with a sensitivity
bFIG. 1 Overall survival according to a clinical T category,
b pretreatment pathological T category, and c post-treatment
pathological T category in 137 patients
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and specificity of CT, EUS, and PET/CT of 39.7% and
77.3%, 42.6% and 75%, and 35.3% and 90.9%,
respectively.17
Our study confirms that patients who did not have any
pretreatment nodal involvement (prepN0) have a better
prognosis than patients who had no residual disease in the
resected lymph nodes (ypN0), but who did have pretreat-
ment nodal involvement (prepN ?).5 This is in contrast
with Donohoe et al.,3 who found that clinically node-pos-
itive patients who had complete nodal response had no
difference in survival compared with initially clinically
node-negative patients. This is probably due to the low
accuracy of clinical N staging. However, in the present
study, multivariable analysis proved combined prepN and
ypN categories as an independent factor of prognosis.
Patients staged prepN ? who became ypN0 after neoad-
juvant chemoradiotherapy had a significantly worse
survival compared with prepN0 patients, with a 2-year
overall survival of 62% vs. 85% (p =0.002) in the com-
bined group of 317 patients. These findings are in concert
with the results of a previously presented study by Nieman
et al.,19 who found a negative prognostic impact of initial
nodal involvement even after complete response after
neoadjuvant chemoradiotherapy. By staging lymph nodes
negative, with no viable cancer cells but the evidence of
tumor necrosis in the resection specimen after neoadjuvant
chemoradiotherapy, the current TNM staging system is
deficient. The previously published data from Shapiro
et al.,5 along with the present results, confirm this thesis as
the prognostic value of pretreatment pathological staging
of lymph nodes is superior to the conventional post-treat-
ment pathological assessment, and patients staged prepN ?
have a significant worse survival compared with patients
staged prepN0.
The question of clinical relevance of pretreatment
pathological staging focuses on the impact of adjuvant
therapy in the case of prepN ? patients. Recently, Hsu and
colleagues studied the benefit of adjuvant treatment in
patients with persistent nodal involvement or with an
increasing T category (non-responders) after neoadjuvant
chemoradiotherapy, and found an improvement in disease-
free survival in non-responders treated after neoadjuvant
chemoradiotherapy, with a significantly reduced rate of
systemic recurrence.20 For the purpose of sterilizing sub-
clinical lymph node metastases or micrometastases by
adjuvant therapy in prepN ? patients, but not in prepN0
bFIG. 2 Overall survival according to a pretreatment clinical N
category, b pretreatment pathological N category, and c post-
treatment pathological N category in 137 patients
A
Log rank P=0.346
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patients, this staging system can achieve clinical signifi-
cance.21 Further studies, based on the proposed
pretreatment pathological staging, should examine the
benefit of adjuvant treatment between different groups of
patients according to the prepN categories.
Limitations of the present study include the inclusion of
patients with both squamous cell carcinomas and adeno-
carcinomas. These subtypes are biologically different;
however, both respond to neoadjuvant chemoradiotherapy
and no statistically significant differential effects were
found in the CROSS trial. Moreover, there was no inter-
action with histological subtype (p for interaction = 0.63),
suggesting that the effect of the combined prepN and ypN
categories is not modified by histology. In the recently
introduced 8th edition of the TNM staging system, ade-
nocarcinoma and squamous cell carcinoma are classified
differently. Moreover, this revised edition accounts for a
new cTNM classification, based on actual clinical stage
(rather than re-iterating the pTNM system based on
patients who had surgery alone), and a new ypTNM system
based on patients receiving neoadjuvant therapy. In the
current paper the (obsolete) 7th edition of the TNM staging
system was used as this paper is an external validation of a
previous study. Therefore, identical methods were
applied.5 Furthermore, the sample size is relatively limited
but was sufficient to validate the initial study and to show
that the combined prepN/ypN stage is an independent
prognostic factor.
Log rank P I vs. II=0.044
Log rank P II vs. III=0.033
Log rank P I vs. III<0.001
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FIG. 3 Overall survival according to the combined scoring of
pretreatment pathological N category and post-treatment
pathological N category in 137 patients. Groups I, II, and III
represent prepN0/ypN0, prepN ?/ypN0, and prepN ?/ypN ?,
respectively
Log rank P I vs. II=0.002
Log rank P II vs. III=0.024
Log rank P I vs. III<0.001
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prepN+/ypN+
prepN0/ypN0
prepN+/ypN0
prepN+/ypN+
113 92 55 34 17 13
Total 317 271 204 141 91 65
Time (months)
O
ve
ra
ll 
su
rv
iv
al
 (%
)
100
90
80
70
60
50
40
30
20
10
0
0 12 24 36 48 60
FIG. 4 Overall survival according to the combined scoring of
pretreatment pathological N category and post-treatment
pathological N category in 317 patients from Cologne and
Rotterdam. Groups I, II, and III represent prepN0/ypN0, prepN ?/
ypN0, and prepN ?/ypN ?, respectively
TABLE 4 Multivariable Cox regression analysis of prognostic
factors related to survival in 317 patients with esophageal cancer
HR 95% CI p value
Age 1.03 1.01–1.05 0.02
Sex
Male 1 (ref) – –
Female 0.67 0.42–1.05 0.08
Histology
Squamous cell carcinoma 1 (ref) – –
Adenocarcinoma 0.91 0.59–1.41 0.68
ypT category
ypT0 1 (ref) – –
ypT1 0.84 (ref) 0.23–3.01 0.79
ypT2 0.71 0.19–2.65 0.61
ypT3/4 1.00 0.28–3.59 1.00
Mandard
1 1 (ref) – –
2 2.08 0.58–7.38 0.26
3 2.36 0.63–8.88 0.20
4 2.41 0.63–9.17 0.20
Combined prepN and ypN
prepN0/ypN0 1 (ref) – –
prepN ?/ypN0 2.17 1.31–3.58 \ 0.01
prepN ?/ypN? 2.84 1.82–4.44 \ 0.01
Bolded p values are statistically significant (i.e. p\ 0.05)
S. Brinkmann et al.
CONCLUSIONS
These results independently confirm the previously
described prognostic value of the pretreatment pathological
staging system. Pretreatment pathological staging is of
additional prognostic value to both cTNM and ypTNM and
should be considered as a new staging parameter.
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